Vesence | $9,000,000 | (Oct 30, 2025)
Sparrow BioAcoustics | $10,000,000 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
Basking Biosciences Inc
United States
- Columbus, OH
- 02/02/2024
- Unknown
- $55,000,000
Basking is developing the first in class agent (BB-031) targeting von Willebrand Factor (VWF) along with a direct acting reversal agent (BB-025) to immediately the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. Basking will initiate a Phase 2 trial in acute ischemic stroke in late 2023 and is exploring further application in pulmonary embolism in preclinical studies. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.
- Industry Biotechnology
- Website https://baskingbiosciences.com/
- LinkedIn https://www.linkedin.com/company/basking-biosciences-inc/
Related People
Rich SheaFounder
United States -
Cary, North Carolina
QUALIFICATIONS SUMMARY
Senior pharmaceutical industry executive with 25 years of progressive leadership, general management and cross functional professional experience.
Significant leadership and management experience in all facets of the pharmaceutical industry including commercial operations, product development, and manufacturing.
Direct experience in a broad range of organizational environments including both entrepreneurial and large, mature organizations.
Specialties: Broad functional management expertise including leadership roles in Sales, Marketing, Finance, Product Development, Alliance Management, Business Strategy, IT and Human Resources
Mem0 | $24,000,000 | (Oct 30, 2025)
Valthos | $30,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
IORGANBIO | $2,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)